bioAffinity Technologies, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BIAF, updated each market day.
BIAF AI Sentiment
AI predicts bioAffinity Technologies, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About bioAffinity Technologies, Inc. Common Stock
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Sector
Exchange
Market Cap
$14,935,601
Cap Tier
Employees
57
Headquarters
SAN ANTONIO, TX
Listed Since
Sept. 1, 2022
Website
BIAF Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BIAF Volatility
bioAffinity Technologies, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
